238 related articles for article (PubMed ID: 16611561)
1. Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa.
Cox E; Verdonck F; Vanrompay D; Goddeeris B
Vet Res; 2006; 37(3):511-39. PubMed ID: 16611561
[TBL] [Abstract][Full Text] [Related]
2. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.
Holmgren J; Adamsson J; Anjuère F; Clemens J; Czerkinsky C; Eriksson K; Flach CF; George-Chandy A; Harandi AM; Lebens M; Lehner T; Lindblad M; Nygren E; Raghavan S; Sanchez J; Stanford M; Sun JB; Svennerholm AM; Tengvall S
Immunol Lett; 2005 Mar; 97(2):181-8. PubMed ID: 15752556
[TBL] [Abstract][Full Text] [Related]
3. ADP-ribosylating bacterial enzymes for the targeted control of mucosal tolerance and immunity.
Lycke N
Ann N Y Acad Sci; 2004 Dec; 1029():193-208. PubMed ID: 15681758
[TBL] [Abstract][Full Text] [Related]
4. Novel strategies using DNA for the induction of mucosal immunity.
McCluskie MJ; Davis HL
Crit Rev Immunol; 1999; 19(4):303-29. PubMed ID: 10530431
[TBL] [Abstract][Full Text] [Related]
5. From toxin to adjuvant: basic mechanisms for the control of mucosal IgA immunity and tolerance.
Lycke N
Immunol Lett; 2005 Mar; 97(2):193-8. PubMed ID: 15752558
[TBL] [Abstract][Full Text] [Related]
6. New generation of mucosal adjuvants for the induction of protective immunity.
Yuki Y; Kiyono H
Rev Med Virol; 2003; 13(5):293-310. PubMed ID: 12931340
[TBL] [Abstract][Full Text] [Related]
7. Neonatal sublingual vaccination with Salmonella proteins and adjuvant cholera toxin or CpG oligodeoxynucleotides induces mucosal and systemic immunity in mice.
Huang CF; Wang CC; Wu TC; Wu KG; Lee CC; Peng HJ
J Pediatr Gastroenterol Nutr; 2008 Mar; 46(3):262-71. PubMed ID: 18376242
[TBL] [Abstract][Full Text] [Related]
8. The B-cell targeted CTA1-DD vaccine adjuvant is highly effective at enhancing antibody as well as CTL responses.
Lycke N
Curr Opin Mol Ther; 2001 Feb; 3(1):37-44. PubMed ID: 11249730
[TBL] [Abstract][Full Text] [Related]
9. Mucosal adjuvants.
Freytag LC; Clements JD
Vaccine; 2005 Mar; 23(15):1804-13. PubMed ID: 15734046
[TBL] [Abstract][Full Text] [Related]
10. Recent developments in mucosal immunomodulatory adjuvants.
Harandi AM; Sanchez J; Eriksson K; Holmgren J
Curr Opin Investig Drugs; 2003 Feb; 4(2):156-61. PubMed ID: 12669375
[TBL] [Abstract][Full Text] [Related]
11. Strategies for optimizing targeting and delivery of mucosal HIV vaccines.
Ahlers JD; Belyakov IM
Eur J Immunol; 2009 Oct; 39(10):2657-69. PubMed ID: 19609978
[TBL] [Abstract][Full Text] [Related]
12. Adoptive transfer of transgenic T cells to study mucosal adjuvants.
Pettini E; Ciabattini A; Pozzi G; Medaglini D
Methods; 2009 Dec; 49(4):340-5. PubMed ID: 19409994
[TBL] [Abstract][Full Text] [Related]
13. Mucosal delivery of vaccines in domestic animals.
Gerdts V; Mutwiri GK; Tikoo SK; Babiuk LA
Vet Res; 2006; 37(3):487-510. PubMed ID: 16611560
[TBL] [Abstract][Full Text] [Related]
14. From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM.
Lycke N
Cell Microbiol; 2004 Jan; 6(1):23-32. PubMed ID: 14678328
[TBL] [Abstract][Full Text] [Related]
15. Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines.
Patel GB; Zhou H; Ponce A; Chen W
Vaccine; 2007 Dec; 25(51):8622-36. PubMed ID: 17959279
[TBL] [Abstract][Full Text] [Related]
16. The immune responses to bacterial antigens encountered in vivo at mucosal surfaces.
Dougan G; Ghaem-Maghami M; Pickard D; Frankel G; Douce G; Clare S; Dunstan S; Simmons C
Philos Trans R Soc Lond B Biol Sci; 2000 May; 355(1397):705-12. PubMed ID: 10874742
[TBL] [Abstract][Full Text] [Related]
17. The use of a mutant TNF-alpha as a vaccine adjuvant for the induction of mucosal immune responses.
Kayamuro H; Abe Y; Yoshioka Y; Katayama K; Nomura T; Yoshida T; Yamashita K; Yoshikawa T; Kawai Y; Mayumi T; Hiroi T; Itoh N; Nagano K; Kamada H; Tsunoda S; Tsutsumi Y
Biomaterials; 2009 Oct; 30(29):5869-76. PubMed ID: 19646748
[TBL] [Abstract][Full Text] [Related]
18. Effect of neonatal sublingual vaccination with native or denatured ovalbumin and adjuvant CpG or cholera toxin on systemic and mucosal immunity in mice.
Huang CF; Wu TC; Chu YH; Hwang KS; Wang CC; Peng HJ
Scand J Immunol; 2008 Nov; 68(5):502-10. PubMed ID: 18822109
[TBL] [Abstract][Full Text] [Related]
19. Transcutaneous immunization with a novel lipid-based adjuvant protects against Chlamydia genital and respiratory infections.
Hickey DK; Aldwell FE; Beagley KW
Vaccine; 2009 Oct; 27(44):6217-25. PubMed ID: 19698810
[TBL] [Abstract][Full Text] [Related]
20. CTA1-DD is an effective adjuvant for targeting anti-chlamydial immunity to the murine genital mucosa.
Cunningham KA; Carey AJ; Lycke N; Timms P; Beagley KW
J Reprod Immunol; 2009 Jul; 81(1):34-8. PubMed ID: 19501917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
